Radiopharm Theranostics (ASX:RAD) said that data presented at the most recent European Molecular Imaging Meeting confirmed positive tumor uptake and favorable biodistribution for RAD202, according to a Monday filing with the Australian bourse.
The human epidermal growth factor receptor 2 or, HER2, is overexpressed in breast cancer as well as several other solid tumors and represents a validated target in oncology. RAD202 is a proprietary single-domain antibody that targets HER2.
The imaging data reported that gallium-68-RAD202 binds specifically to the receptor in HER2-positive xenografts, with a high tumor-to-background ratio. Imaging with it resulted in specific accumulation in the tumor and low uptake in non-target organs, except for the bladder and kidney.
The removal of a polyhistidine tag from the RAD202 nanobody, which impacts biodistribution and tumor targeting, was validated to be superior for positron emission tomography imaging due to the higher tumor-to-organ ratio.
Therapy with lutetium-177-RAD202 was well-tolerated, confirming a reduction in tumor volume, significantly prolonging survival time.
A dose escalation phase one study of lutetium-177-RAD202 is currently in the recruiting phase in Australia. It is designed to evaluate the safety and preliminary activity of the radiotherapeutic product in patients with advanced HER2-positive solid tumors.
Its shares jumped 11% on market close on Monday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。